Uncover the next big thing with financially sound penny stocks that balance risk and reward.
To be a confident shareholder in Apellis Pharmaceuticals today, you need to believe in the company’s ability to turn breakthrough approvals into robust, sustainable growth while managing its pronounced dependency on a narrow product lineup. The FDA approval of EMPAVELI for rare kidney diseases is an important catalyst, expanding Apellis’s addressable market in the near term, but does not fundamentally alter the ongoing revenue concentration risk that weighs most heavily on the business. If EMPAVELI and SYFOVRE face setbacks, the bottom line could be quickly impacted.
Among recent company actions, Apellis’s $300 million capped royalty purchase agreement with Sobi stands out as especially relevant. This arrangement provides immediate financial flexibility as the company moves to commercialize EMPAVELI in new indications, helping to offset current losses and fund ongoing development, which is important while Apellis builds toward broader portfolio diversification.
However, even with new approvals, there is still the risk that heavy reliance on just two commercial assets leaves the business exposed if competitive threats or reimbursement changes emerge, investors should be aware that ...
Read the full narrative on Apellis Pharmaceuticals (it's free!)
Apellis Pharmaceuticals' outlook anticipates $1.2 billion in revenue and $179.9 million in earnings by 2028. This scenario assumes a 17.1% annual revenue growth rate and a $403.6 million improvement in earnings from the current level of -$223.7 million.
Uncover how Apellis Pharmaceuticals' forecasts yield a $35.60 fair value, a 55% upside to its current price.
Simply Wall St Community members have fair value estimates for Apellis Pharmaceuticals ranging from US$35.60 to US$110.99, based on three distinct analyses. While optimism around the addressable market grows after EMPAVELI’s approval, you should weigh how ongoing reliance on SYFOVRE and EMPAVELI shapes the company’s future resilience.
Explore 3 other fair value estimates on Apellis Pharmaceuticals - why the stock might be worth just $35.60!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocks
Try a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.